Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Invested Capital (2016 - 2026)

Ani Pharmaceuticals' Invested Capital history spans 16 years, with the latest figure at $853.5 million for Q4 2025.

  • On a quarterly basis, Invested Capital rose 17.46% to $853.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $853.5 million, a 17.46% increase, with the full-year FY2025 number at $853.5 million, up 17.46% from a year prior.
  • Invested Capital hit $853.5 million in Q4 2025 for Ani Pharmaceuticals, up from $822.7 million in the prior quarter.
  • Over the last five years, Invested Capital for ANIP hit a ceiling of $853.5 million in Q4 2025 and a floor of $222.9 million in Q3 2021.
  • Historically, Invested Capital has averaged $416.7 million across 5 years, with a median of $303.3 million in 2022.
  • Biggest five-year swings in Invested Capital: soared 11643.08% in 2021 and later tumbled 61.34% in 2025.
  • Tracing ANIP's Invested Capital over 5 years: stood at $296.9 million in 2021, then rose by 0.05% to $297.0 million in 2022, then dropped by 1.01% to $294.0 million in 2023, then surged by 147.16% to $726.6 million in 2024, then increased by 17.46% to $853.5 million in 2025.
  • Business Quant data shows Invested Capital for ANIP at $853.5 million in Q4 2025, $822.7 million in Q3 2025, and $318.9 million in Q2 2025.